CAMBRIDGE, MA – September 5th , 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Anthony B. El-Khoueiry, MD, Associate Director for Clinical Research and Phase I Program Director at the University of Southern California, Norris Comprehensive Cancer Center, and Associate Professor of Clinical Medicine at the Keck School … Continued

CAMBRIDGE, MA – August 15, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO’s HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications preselected by HiFiBiO’s … Continued

CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued